Send Message
Home ProductsSmall Volume Injection

Medicine Glass Bottle Packing Ofloxacin And Glucose Injections For Pain

Certification
China ANHUI BBCA PHARMACEUTICAL CO.,LTD certification
China ANHUI BBCA PHARMACEUTICAL CO.,LTD certification
Customer Reviews
Dear Sunny, Thank you so much for your company for quick shipment of the goods,we have caught up with the market. Best Rgeards, Erci Mohammad

—— Eric Mohammad

Dear Sunny, The quality of Paracetamol is very good,our customer is very satisfied.Thank you so much! Best Regards, Jean Green

—— Jean Green

I'm Online Chat Now

Medicine Glass Bottle Packing Ofloxacin And Glucose Injections For Pain

Medicine Glass Bottle Packing Ofloxacin And Glucose Injections For Pain
Medicine Glass Bottle Packing Ofloxacin And Glucose Injections For Pain

Large Image :  Medicine Glass Bottle Packing Ofloxacin And Glucose Injections For Pain

Product Details:
Place of Origin: China
Brand Name: BBCA
Certification: GMP
Model Number: BBCA18022402
Payment & Shipping Terms:
Price: Negotiated
Packaging Details: 40 Glass Bottles/Carton
Delivery Time: 25 DAYS AFTER PAYMENT
Payment Terms: L/C, T/T, , MoneyGram, L/C, T/T, , MoneyGram

Medicine Glass Bottle Packing Ofloxacin And Glucose Injections For Pain

Description
Place Of Origin: China (Mainland) Brand Name: BBCA
Other Names: Pharmaceutical Transfusion Glass Bottle Packing Ofloxacin And Glucose Injection Grade: Medicine Grade
Dosage Form: Injection
High Light:

metronidazole injection

,

glucose injection

Pharmaceutical Transfusion Medicine Glass Bottle Packing Ofloxacin And Glucose Injection

Specifications

1. Product Name: Pharmaceutical Transfusion Glass Bottle packing Ofloxacin and Glucose Injection

 

2. Component: Ofloxacin and glucose.Main ingredients: ofloxacin.

 

3. Appearance: This product is light yellow or yellowish green transparent liquid.

 

4. Indications: 

Suitable for sensitive bacteria caused by:
  1. Urinary reproductive system infection, including simple and complicated urinary tract infection, bacterial prostatitis, bacteria neisseria gonorrhea urethritis and cervicitis (including enzyme production strains caused by).
  2. Respiratory tract infections, including sensitive acute bronchial infection caused by gram-negative bacilli and lung infection.
  3. Gastrointestinal tract infection, by shigella, salmonella and e. coli to produce enterotoxin, moisture, deputy hemolytic bacterium vibrio, etc.
  4. Typhoid.
  5. Bone and joint infections.
  6. Skin soft tissue infection.
  7. Sepsis and systemic infection.

 

5. Specifications: 100ml: 0.2g

 

6. Usage and Dosage: 

 

Intravenous drip slowly.Adults often usage:
  1.Bronchial infection, pulmonary infection: a 0.3 g, 2 times a day, treatment 7 ~ 14 days.
  2.Acute simple lower urinary tract infection: a 0.2 g, 2 times a day, course of 5 to 7 days;Complexity   urinary tract infection: a 0.2 g, 2 times a day, 10 ~ 14.
  3.Prostatitis: a 0.3 g, 2 times a day, the course of six weeks;Chlamydia cervicitis or urethritis, a 0.3 g, 2 times a day, the course of 7 ~ 14 days.
  4.Simple gonorrhea: 0.4 g at a time, a single dose.
  5.Typhoid fever: a 0.3 g, 2 times a day, course of 10 ~ 14.
  6.Pseudomonas aeruginosa infection or heavier infection: dose may be increased to 0.4 g, 2 times a day.

 

7. Drug interactions: 

 

  1.Urine, agents can reduce the product solubility in the urine, cause crystallization urine and kidney toxicity.
  2.Quinolone antibacterial and theophylline class share may be due to combined with the cytochrome P450 when parts of a competitive inhibition, seriously reduce the liver to eliminate theophylline class, blood elimination half-life (t1/2 beta), blood drug concentration increases, theophylline poisoning symptoms, such as nausea, vomiting, tremor, anxiety, excitement, convulsions, heart palpitations and so on.Metabolic effects of theophylline, although small, but share when should still determination of theophylline blood drug concentration and dose adjustment.
  3.This product with ring spore share, can make the ring spore elevated blood drug concentration, must monitor ring spore blood concentration, and adjust the dosage.
  4.This product and share the anti-clotting drug warfarin is smaller in the latter the anticoagulant effect of enhanced, but also should closely monitor patients when sharing the prothrombin time.
  5.Probenecid can reduce the product since the renal tubular secretion by about 50%, when share can produce because of the product increased blood levels of toxicity.
  6.The product can interfere with the metabolism of caffeine, which can lead to eliminate caffeine reduce, eliminate blood half-life (t1/2 beta) extended, and the central nervous system toxicity may be produced.

 

8. Contraindications: This article and fluoroquinolone drug allergy patients disabled.

 

9. Pharmacological mechanisms: The product widely distributed to the group after the treatment, body fluids, organizations often more than the concentration of blood drug concentration and effective level.This product can be through the placental barrier.Protein binding rate of 20% ~ 25%.
This product mainly prototype medicine since renal excretion, a small amount (3%) in hepatic metabolism.Urine metabolites are rare.This product to prototype from feces to remove a small amount, 24 hours a day and 48 hours after the treatment the cumulative discharge of dosage of 1.6% and 1.6% respectively.This product can also be through breast milk secretion.

 

10. Storage: Protect from light, airtight preservation.

 

11. Package: 100ml/glass bottle; 40 glass bottles/carton 

 

 

 

Contact Details
ANHUI BBCA PHARMACEUTICAL CO.,LTD

Contact Person: Mr. Eric

Tel: +86-551-64846195

Fax: 86-551-64846082

Send your inquiry directly to us (0 / 3000)